...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience.
【24h】

Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience.

机译：T1声门癌放疗三周：科视和皇家马斯登医院的经验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND PURPOSE: Radiotherapy for laryngeal carcinoma is conventionally given over a 6-7-week period. However, in a number of UK centres early lesions are treated over 3 weeks. We review recent results of this policy and discuss the reasons why short treatment times may be advantageous.MATERIALS AND METHODS: Two hundred patients (100 from each centre) with T1 glottic invasive squamous cell carcinoma treated with definitive radiotherapy between 1989 and 1997 were analysed. The median age was 68 years. All patients received once daily fractionation, 5 days a week to a total tumour dose of 50.0-52.5 Gy in 16 fractions over 21 days; the fraction size ranged from 3.12 to 3.28 Gy. The median follow-up period was 5 years and 10 months.RESULTS: The 5-year local control rates with radiotherapy for the whole group was 93%; there were 14 recurrences of which seven were salvaged by laryngectomy giving an ultimate local control of 96%. The 5-year overall survival was 80% and cause specific survival at 5 years was 97%. Univariate analysis revealed that T1 substaging (P=0.82) and anterior commissure involvement (P=0.47) did not significantly influence local control. A severe late radiation complication was seen in only one patient who continued to smoke heavily after treatment. There were no severe acute complications.CONCLUSIONS: Once daily radiotherapy over 3 weeks gives excellent local control in patients with T1 glottic squamous-cell carcinoma and has a low rate of severe complications. The short overall treatment time and large fraction size may be advantageous in radiotherapy of these well-differentiated tumours.
机译：背景与目的：喉癌的放疗通常在6-7周内进行。但是，在英国的一些中心，早期病变的治疗超过3周。我们回顾了该政策的最新结果，并讨论了缩短治疗时间可能有利的原因。材料与方法：分析了1989年至1997年间200例接受了明确放疗的T1声门浸润性鳞状细胞癌患者（每个中心100例）。中位年龄是68岁。所有患者每天接受一次分次治疗，每周5天，在21天内分16次分次给予总肿瘤剂量50.0-52.5 Gy。馏分的大小范围为3.12至3.28 Gy。结果：中位随访期为5年10个​​月。结果：整组患者5年局部放疗控制率为93％。有14例复发，其中7例通过喉切除术挽救，最终局部控制率为96％。 5年总生存率为80％，5年特定原因生存率为97％。单因素分析显示，T1分期（P = 0.82）和前连合受累（P = 0.47）不会显着影响局部控制。仅在治疗后继续大量吸烟的一名患者中发现了严重的晚期放射并发症。结论：T1声门鳞状细胞癌患者每天放疗超过3周，可以很好地进行局部控制，严重并发症发生率低。较短的总体治疗时间和较大的馏分大小可能有利于这些分化良好的肿瘤的放射治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号